{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:09:29Z","timestamp":1790816969116,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/34\/E\/NZ7\/00056"],"award-info":[{"award-number":["2019\/34\/E\/NZ7\/00056"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bbadis.2024.167574","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T11:21:11Z","timestamp":1731756071000},"page":"167574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Molecular mechanisms restoring olaparib efficacy through ATR\/CHK1 pathway inhibition in olaparib-resistant BRCA1\/2MUT ovarian cancer models"],"prefix":"10.1016","volume":"1871","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3896-8327","authenticated-orcid":false,"given":"\u0141ukasz","family":"Biega\u0142a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2170-1909","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Statkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3475-441X","authenticated-orcid":false,"given":"Arkadiusz","family":"Gajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6545-579X","authenticated-orcid":false,"given":"Izabela","family":"Szymczak-Pajor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7496-2489","authenticated-orcid":false,"given":"Natalia","family":"Rusetska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6864-0704","authenticated-orcid":false,"given":"Agnieszka","family":"\u015aliwi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3439-9032","authenticated-orcid":false,"given":"Agnieszka","family":"Marczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-7328","authenticated-orcid":false,"given":"Micha\u0142","family":"Mikula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-1693","authenticated-orcid":false,"given":"Aneta","family":"Rogalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bbadis.2024.167574_bb0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11912-020-00933-8","article-title":"First-line Management of Advanced High-Grade Serous Ovarian Cancer","volume":"22","author":"Mahmood","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bbadis.2024.167574_bb0010","doi-asserted-by":"crossref","first-page":"1162665","DOI":"10.3389\/fphar.2023.1162665","article-title":"Olaparib and advanced ovarian cancer: summary of the past and looking into the future","volume":"14","author":"Maiorano","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbadis.2024.167574_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian Cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2024.167574_bb0020","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157644","article-title":"Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer","volume":"15","author":"Veneziani","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"10.1016\/j.bbadis.2024.167574_bb0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0030","doi-asserted-by":"crossref","first-page":"21884","DOI":"10.1038\/s41598-023-48153-x","article-title":"Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer","volume":"13","author":"Burdett","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","article-title":"A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","volume":"32","author":"Tobalina","year":"2021","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bbadis.2024.167574_bb0040","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e44","article-title":"PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies","volume":"33","author":"Miller","year":"2022","journal-title":"J. Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.bbadis.2024.167574_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241511890","article-title":"An overview of PARP resistance in ovarian Cancer from a molecular and clinical perspective","volume":"24","author":"Cordani","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bbadis.2024.167574_bb0050","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0055","doi-asserted-by":"crossref","first-page":"22659","DOI":"10.1038\/s41598-023-50151-y","article-title":"Targeted inhibition of the ATR\/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells","volume":"13","author":"Biega\u0142a","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0060","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bbadis.2024.167574_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071807","article-title":"Combinations of ATR, Chk1 and Wee1 inhibitors with Olaparib are active in Olaparib resistant Brca1 proficient and deficient murine ovarian cells","volume":"14","author":"Chiappa","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.bbadis.2024.167574_bb0070","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","article-title":"The CHK1 inhibitor Prexasertib exhibits monotherapy activity in high-grade serous ovarian Cancer models and sensitizes to PARP inhibition","volume":"25","author":"Parmar","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbadis.2024.167574_bb0075","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.bbadis.2024.167574_bb0080","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian Cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40880-018-0329-5","article-title":"Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response","volume":"38","author":"Zhang","year":"2018","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"10.1016\/j.bbadis.2024.167574_bb0095","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.celrep.2017.10.015","article-title":"A targetable EGFR-dependent tumor-initiating program in breast Cancer","volume":"21","author":"Savage","year":"2017","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.bbadis.2024.167574_bb0100","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1158\/1535-7163.MCT-13-0159","article-title":"Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models","volume":"12","author":"Xu","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.bbadis.2024.167574_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123857","article-title":"Proteomic resistance biomarkers for PI3K inhibitor in triple negative breast Cancer patient-derived xenograft models","volume":"12","author":"Guo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.bbadis.2024.167574_bb0110","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/1878-0261.13510","article-title":"Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts","volume":"17","author":"Reissig","year":"2023","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neo.2020.11.005","article-title":"Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine","volume":"23","author":"Rivera","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbadis.2024.167574_bb0120","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.6586","article-title":"Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX)","volume":"7","author":"Malcolm","year":"2019","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.bbadis.2024.167574_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031563","article-title":"Vinorelbine improves the efficacy of Sorafenib against hepatocellular carcinoma: a promising therapeutic approach","volume":"25","author":"Ng","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13058-017-0878-6","article-title":"Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer","volume":"19","author":"Arango","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbadis.2024.167574_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"8 Suppl","key":"10.1016\/j.bbadis.2024.167574_bb0140","first-page":"4244s","article-title":"Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors","volume":"46","author":"McCarty","year":"1986","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bbadis.2024.167574_bb0145","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbadis.2024.167574_bb0150","article-title":"PARP inhibitor resistance in breast and gynecological cancer: resistance mechanisms and combination therapy strategies","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbadis.2024.167574_bb0155","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3892\/ol.2017.5582","article-title":"Genome-wide analysis of gynecologic cancer: the Cancer genome atlas in ovarian and endometrial cancer","volume":"13","author":"Iijima","year":"2017","journal-title":"Oncol. Lett."},{"issue":"10","key":"10.1016\/j.bbadis.2024.167574_bb0160","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonzalez-Martin","year":"2023","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.bbadis.2024.167574_bb0165","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/bjc.2014.345","article-title":"Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours","volume":"111","author":"Del Conte","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13048-019-0594-1","article-title":"Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China","volume":"12","author":"Ni","year":"2019","journal-title":"J. Ovarian Res."},{"issue":"21","key":"10.1016\/j.bbadis.2024.167574_bb0175","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0180","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bbadis.2024.167574_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/cells12071038","article-title":"Olaparib-resistant BRCA2MUT ovarian Cancer cells with restored BRCA2 abrogate Olaparib-induced DNA damage and G2\/M arrest controlled by the ATR\/CHK1 pathway for survival","volume":"12","author":"Biega\u0142a","year":"2023","journal-title":"Cells"},{"issue":"15","key":"10.1016\/j.bbadis.2024.167574_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153919","article-title":"Transforming growth factor Beta and Epithelial to mesenchymal transition Alter homologous recombination repair gene expression and sensitize BRCA wild-type ovarian Cancer cells to Olaparib","volume":"15","author":"Roberts","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbadis.2024.167574_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105235","article-title":"10% body weight (gain) change as criterion for the maximum tolerated dose: a critical analysis","volume":"134","author":"van Berlo","year":"2022","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbadis.2024.167574_bb0200","article-title":"What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization classification of female genital tumors","volume":"11","author":"De Leo","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"10.1016\/j.bbadis.2024.167574_bb0205","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"15","key":"10.1016\/j.bbadis.2024.167574_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153774","article-title":"Establishment and molecular characterization of an in vitro model for PARPi-resistant ovarian Cancer","volume":"15","author":"Klotz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bbadis.2024.167574_bb0215","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molcel.2011.06.019","article-title":"ATR autophosphorylation as a molecular switch for checkpoint activation","volume":"43","author":"Liu","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbadis.2024.167574_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"20","key":"10.1016\/j.bbadis.2024.167574_bb0225","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1128\/MCB.00447-06","article-title":"Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit","volume":"26","author":"Leung-Pineda","year":"2006","journal-title":"Mol. Cell. Biol."},{"issue":"33","key":"10.1016\/j.bbadis.2024.167574_bb0230","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41388-020-1383-4","article-title":"Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer","volume":"39","author":"Nair","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2024.167574_bb0235","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/801594","article-title":"BRCA1 forms a functional complex with gamma-H2AX as a late response to genotoxic stress","volume":"2010","author":"Krum","year":"2010","journal-title":"J. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0240","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1038\/s41467-020-16926-x","article-title":"DNA double-strand breaks induce H2Ax phosphorylation domains in a contact-dependent manner","volume":"11","author":"Collins","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2024.167574_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101928","article-title":"PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer","volume":"42","author":"Hong","year":"2021","journal-title":"Redox Biol."},{"issue":"6","key":"10.1016\/j.bbadis.2024.167574_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060838","article-title":"The role of epithelial-to-mesenchymal plasticity in ovarian Cancer progression and therapy resistance","volume":"11","author":"Loret","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"Suppl. 1","key":"10.1016\/j.bbadis.2024.167574_bb0255","article-title":"Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management","volume":"73","author":"da Cunha Colombo Bonadio","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"issue":"3","key":"10.1016\/j.bbadis.2024.167574_bb0260","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cell.2016.05.069","article-title":"Integrated Proteogenomic characterization of human high-grade serous ovarian Cancer","volume":"166","author":"Zhang","year":"2016","journal-title":"Cell"},{"issue":"60","key":"10.1016\/j.bbadis.2024.167574_bb0265","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.18632\/oncotarget.20722","article-title":"Detection of BRCA1\/2 mutations in circulating tumor DNA from patients with ovarian cancer","volume":"8","author":"Ratajska","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2024.167574_bb0270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.dnarep.2019.02.002","article-title":"The role of dePARylation in DNA damage repair and cancer suppression","volume":"76","author":"Kassab","year":"2019","journal-title":"DNA Repair (Amst)"},{"issue":"6","key":"10.1016\/j.bbadis.2024.167574_bb0275","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","article-title":"Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality","volume":"33","author":"Gogola","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2019.01.015","article-title":"53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer","volume":"153","author":"Hurley","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0285","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0290","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13045-021-01196-x","article-title":"VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status","volume":"14","author":"Bizzaro","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.bbadis.2024.167574_bb0295","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian Cancer models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbadis.2024.167574_bb0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.gim.2021.08.016","article-title":"Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants","volume":"24","author":"Li","year":"2022","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.bbadis.2024.167574_bb0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neo.2021.12.002","article-title":"Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer","volume":"24","author":"Wilson","year":"2022","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.bbadis.2024.167574_bb0310","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41419-022-05257-y","article-title":"Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer","volume":"13","author":"Tang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"17","key":"10.1016\/j.bbadis.2024.167574_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179826","article-title":"A double-edged sword: the two faces of PARylation","volume":"23","author":"Kang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2024.167574_bb0320","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/OTT.S272199","article-title":"Ovarian cancer therapy: homologous recombination deficiency as a predictive biomarker of response to PARP inhibitors","volume":"15","author":"Miller","year":"2022","journal-title":"Onco. Targets. Ther."},{"issue":"24","key":"10.1016\/j.bbadis.2024.167574_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246288","article-title":"Patient-derived xenografts of high-grade serous ovarian Cancer subtype as a powerful tool in pre-clinical research","volume":"13","author":"Cybula","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443924005684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443924005684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:54:09Z","timestamp":1778770449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443924005684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0925443924005684"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2024.167574","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms restoring olaparib efficacy through ATR\/CHK1 pathway inhibition in olaparib-resistant BRCA1\/2MUT ovarian cancer models","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2024.167574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"167574"}}